文献速递血脂与心血管预防冠心病

抗PCSK9疫苗AT04A降低APOE*3Leiden.CETP小鼠胆固醇、血管炎症与动脉粥样硬化

The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.
PubMed 文献 · Eur Heart J · 2017-01-01

在动脉粥样硬化模型APOE*3Leiden.CETP小鼠中,AT04A抗PCSK9疫苗诱导持续高抗体水平,使血浆总胆固醇降低53%、LDLc下降,并显著减少炎症标志物、动脉粥样硬化病变面积(-64%)及增加无病变主动脉节段(+119%)。

要点

  • AT04A疫苗诱导持久抗PCSK9抗体,显著降低血浆总胆固醇和LDLc。
  • 疫苗降低SAA、MIP-1β、MDC、SCF、VEGF-A等炎症标志物。
  • 疫苗减少动脉粥样硬化病变面积并增加无病变主动脉节段。

核心结论

  • AT04A疫苗在小鼠中诱导有效抗PCSK9免疫反应,降低血脂、炎症和主动脉粥样硬化病变。

研究设计与样本

  • 在APOE*3Leiden.CETP小鼠中比较对照与AT04A疫苗组,喂食西式饮食18周。

主要发现

  • AT04A诱导高且持久的抗PCSK9抗体水平。
  • 血浆总胆固醇降低53%(P < 0.001),LDLc下降。
  • SAA、MIP-1β/CCL4、MDC/CCL22、SCF、VEGF-A等炎症标志物显著减少。
  • 动脉粥样硬化病变面积减少64%(P = 0.004),无病变主动脉节段增加119%(P = 0.026)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hypercholesterolaemia and atherosclerosis. PCSK9 binds to the low density lipoprotein receptor and enhances its degradation, which leads to the reduced clearance of low density lipoprotein cholesterol (LDLc) and a higher risk of atherosclerosis. In this study, the AT04A anti-PCSK9 vaccine was evaluated for its therapeutic potential in ameliorating or even preventing coronary heart disease in the atherogenic APOE*3Leiden.CETP mouse model. METHODS AND RESULTS: Control and AT04A vaccine-treated mice were fed western-type diet for 18 weeks. Antibody titres, plasma lipids, and inflammatory markers were monitored by ELISA, FPLC, and multiplexed immunoassay, respectively. The progression of atherosclerosis was evaluated by histological analysis of serial cross-sections from the aortic sinus. The AT04A vaccine induced high and persistent antibody levels against PCSK9, causing a significant reduction in plasma total cholesterol (-53%, P < 0.001) and LDLc compared with controls. Plasma inflammatory markers such as serum amyloid A (SAA), macrophage inflammatory protein-1β (MIP-1β/CCL4), macrophage-derived chemokine (MDC/CCL22), cytokine stem cell factor (SCF), and vascular endothelial growth factor A (VEGF-A) were significantly diminished in AT04A-treated mice. As a consequence, treatment with the AT04A vaccine resulted in a decrease in atherosclerotic lesion area (-64%, P = 0.004) and aortic inflammation as well as in more lesion-free aortic segments (+119%, P = 0.026), compared with control. CONCLUSIONS: AT04A vaccine induces an effective immune response against PCSK9 in APOE*3Leiden.CETP mice, leading to a significant reduction of plasma lipids, systemic and vascular inflammation, and atherosclerotic lesions in the aorta.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Landlinger C, Pouwer MG, Juno C, et al. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. Eur Heart J. 2017. PMID: 28637178. doi:10.1093/eurheartj/ehx260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。